Tel: +44 (0) 1904 406082

Abingdon Health Ltd, is pleased to announce the appointment of Dr. David Pritchard as Chief Technology Officer.

David has a track record of success within the medical diagnostics industry having spent the last twenty years at Axis-Shield Diagnostics, most recently as Head of Research. At Axis-Shield David was responsible for a Research and Development (R&D) team of 50 staff involved in the identification, evaluation, development and commercialisation of novel and challenging immunoassays. David is a member of the Industrial Advisory Group of the Institute of Bio-Sensing Technology and holds a PhD from the University of Glasgow in the development of multi-analyte biosensors.

David will be responsible for the Group’s lateral flow immunoassay and reader development programmes based at the Group’s Birmingham site including the management of the Group’s development of the next generation lateral flow biosensor system in partnership with Sumitomo Chemical Corporation. David will be a member of the Group’s Executive Team and will report into Chris Yates, CEO.

Dene Baldwin, current Technical Director, has decided to retire but will continue to work with Abingdon Health going forward in a consultancy capacity.

Chris Yates, CEO, commented:

“I would like to thank Dene Baldwin on behalf of the Board and all employees for his tremendous contribution to the development of Abingdon Health over the past two years. During this period we have CE-marked five products and made significant progress on the development of our reader technology. We are delighted that we will still be able to call on Dene’s skills and experience in the future but we also wish him well in his retirement from day-to-day activities.

I am delighted to welcome Dr. David Pritchard to Abingdon Health. It is a real coup for Abingdon Health to secure the services of David and his appointment underlines our ambition to build Abingdon Health into a leading provider of technology-led immunoassay products. David has a wealth of experience in the development of both immunoassays and near-patient reader systems and his contribution will be invaluable as we look to execute on our ambitious growth plans.”